Viridian Therapeutics (VRDN) News Today → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free VRDN Stock Alerts $12.51 -0.52 (-3.99%) (As of 01:35 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 6.2%marketbeat.com - April 24 at 6:51 PMKnights of Columbus Asset Advisors LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - April 21 at 6:39 AMViridian Therapeutics (NASDAQ:VRDN) Sees Strong Trading Volumeamericanbankingnews.com - April 21 at 2:32 AMViridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volumemarketbeat.com - April 19 at 11:58 AMViridian Therapeutics (NASDAQ: VRDN)fool.com - April 13 at 3:28 PMViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Vanguard Group Inc.marketbeat.com - April 11 at 4:11 AMViridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%marketbeat.com - April 10 at 2:51 PMBuy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potentialmarkets.businessinsider.com - April 6 at 2:51 AMViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 4 at 4:01 PMViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Buy" from Brokeragesmarketbeat.com - April 4 at 2:16 AMViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLCmarketbeat.com - April 1 at 4:23 AMVIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firmprnewswire.com - March 29 at 9:00 AMAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)markets.businessinsider.com - March 25 at 10:01 PMViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% Following Analyst Downgrademarketbeat.com - March 22 at 12:27 PMB. Riley Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $25.00marketbeat.com - March 21 at 10:55 AMBuy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Marketmarkets.businessinsider.com - March 20 at 8:21 PMUnveiling 4 Analyst Insights On Viridian Therapeuticsmarkets.businessinsider.com - March 20 at 3:20 PMViridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at Needham & Company LLCmarketbeat.com - March 20 at 1:44 PMFinding the Next Big Winners: 3 Stocks You Can Snag for Under $20investorplace.com - March 19 at 6:51 PMVRDN Sep 2024 20.000 putfinance.yahoo.com - March 16 at 8:46 AMVRDN Apr 2024 20.000 putfinance.yahoo.com - March 16 at 8:46 AMSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firmstockhouse.com - March 15 at 11:23 PMViridian Therapeutics (NASDAQ:VRDN) Shares Down 8.4% marketbeat.com - March 12 at 1:24 PMVRDN Makes Bullish Cross Above Critical Moving Averagenasdaq.com - March 9 at 2:40 PMSchonfeld Strategic Advisors LLC Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 9 at 5:42 AMViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 6 at 4:01 PMViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conferencefinance.yahoo.com - March 5 at 10:27 AMCharles Schwab Investment Management Inc. Increases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 5 at 4:35 AMConnor Clark & Lunn Investment Management Ltd. Sells 67,587 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 2 at 6:17 AMBraidwell LP Acquires 528,882 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - March 1 at 10:18 AMViridian Therapeutics, Inc. Expected to Post FY2024 Earnings of ($5.72) Per Share (NASDAQ:VRDN)marketbeat.com - March 1 at 8:02 AMBuy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potentialmarkets.businessinsider.com - March 1 at 8:01 AMBuy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial Potentialmarkets.businessinsider.com - February 29 at 3:56 PMViridian Therapeutics, Inc. Forecasted to Earn FY2027 Earnings of $5.61 Per Share (NASDAQ:VRDN)marketbeat.com - February 29 at 9:44 AMViridian Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - February 29 at 5:55 AMViridian Therapeutics (NASDAQ:VRDN) Trading Up 6.8% on Analyst Upgrademarketbeat.com - February 28 at 11:27 AMViridian Therapeutics (NASDAQ:VRDN) Announces Earnings Resultsmarketbeat.com - February 28 at 10:42 AMViridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLCmarketbeat.com - February 28 at 8:30 AMWedbush Boosts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $40.00marketbeat.com - February 28 at 8:30 AMBuy Rating Affirmed for Viridian Therapeutics Amid Strong Drug Pipeline Progress and Robust Financial Positionmarkets.businessinsider.com - February 28 at 7:48 AMViridian Therapeutics GAAP EPS of -$1.35msn.com - February 28 at 1:57 AMViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Resultsbusinesswire.com - February 27 at 4:01 PMCitigroup Inc. Buys 30,564 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - February 25 at 4:50 AMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)markets.businessinsider.com - February 22 at 11:45 AMVRDN Mar 2024 30.000 putfinance.yahoo.com - February 17 at 8:00 AMViridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officerfinance.yahoo.com - February 16 at 10:44 AMViridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officerbusinesswire.com - February 16 at 8:00 AMBarclays PLC Decreases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - February 16 at 4:31 AMViridian Therapeutics, Inc. to Post FY2024 Earnings of ($3.83) Per Share, Leerink Partnrs Forecasts (NASDAQ:VRDN)marketbeat.com - February 8 at 8:13 AMViridian Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.93) Per Share (NASDAQ:VRDN)marketbeat.com - February 7 at 8:05 AM Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. VRDN Media Mentions By Week VRDN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼0.880.43▲Average Medical News Sentiment VRDN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼43▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FLGT News Today CSTL News Today VCYT News Today CDNA News Today SERA News Today PMD News Today GH News Today ARWR News Today RDNT News Today FTRE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
